[1] 中华医学会皮肤性病分会银屑病学组. 中国银屑病治疗专家共识(2014版)[J]. 中华皮肤科杂志, 2014, 47(3):213-215. [2] 丁晓岚,王婷琳,沈佚葳,等.中国六省市银屑病流行病学调查[J].中国皮肤性病学杂志,2010,24(7):598-601. [3] CFDA.国家食品药品监督管理局关于修订复方青黛丸(浓缩丸、片、胶囊)说明书的通知[EB/OL].(2013-03-28)[2019-03-13]. http://www.cdr-adr.org.cn/tzgg/ywgz/201303/t20130328_5385.html. [4] CFDA.总局关于修订维胺酯口服制剂说明书的公告[EB/OL].(2016-11-23)[2019-03-13]. http://www.cdr-adr.org.cn/tzgg/ywgz/201611/t20161123_18045.html . [5] World Health Organization(WHO),Uppsala Monitoring Centre.The use of the WHO-UMC syst em for standardised case causali-tyassessment. WHO[EB/OL].(2012-06-11)[2019-03-13].http://www.who-umc.org/graphics/26649. [6] 于乐成,茅益民,陈成伟.药物性肝损伤诊治指南[J].实用肝脏病杂志,2017,20(2):257-274. [7] CFDA.药品不良反应报告和监测管理办法[EB/OL].(2011-05-04)[2019-03-13].http://www.nmpa.gov.cn/WS04/CL2196/323845.html. [8] Navarro V J, Barnhart H, Bonkovsky H L, et al.Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network[J]. Hepatology, 2014, 60(4):1399-1408. [9] 何婷婷,钟学文,张宁,等.187例中草药及其制剂导致肝损伤病例前瞻性临床研究[J].肝脏,2018,23(8):666-669. [10] 王开利,赵军,邢汉前,等.中草药治疗银屑病致药物性肝病34例临床分析[J].军医进修学院学报,2012,33(10):1059-1060,1063. [11] 肖小河,Herve Louet,Victor Navarro,等.传统药物安全用药北京宣言[J].药学学报,2018,53(11):1930. [12] Menter A, Korman N J, Elmets C A, et al.Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions[J]. Journal of the American Academy of Dermatology, 2011, 65(1):0-174. [13] 王雨,林志健,王笑,等.含补骨脂中成药肝损伤案例的分析与警戒思考[J].中国药物警戒,2018,15(5):300-303. [14] 葛斐林,牛明,韩紫欣,等.白鲜皮制剂相关肝损伤的药物流行病学特征分析[J/OL].中国中药杂志:1-9.( 2018-12-18)[2019-03-13].https://doi.org/10.19540/j.cnki.cjcmm.20181217.001. |